| scholarly article | Q13442814 |
| P50 | author | Sue S. Yom | Q38327769 |
| Joseph M Huryn | Q40667627 | ||
| P2093 | author name string | Cherry L Estilo | |
| Adepitan A Owosho | |||
| Adi Z Sax | |||
| Kant Wu | |||
| See Toh Yoong Liang | |||
| P2860 | cites work | Denosumab and bisphosphonates: different mechanisms of action and effects. | Q34154083 |
| Tooth extractions in high-risk patients under bisphosphonate therapy and previously affected with osteonecrosis of the jaws: surgical protocol supported by low-level laser therapy. | Q35615419 | ||
| Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients | Q36667402 | ||
| Case series of 589 tooth extractions in patients under bisphosphonates therapy. Proposal of a clinical protocol supported by Nd:YAG low-level laser therapy. | Q37063592 | ||
| Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. | Q37224099 | ||
| Osteonecrosis of the jaw associated with ziv-aflibercept | Q37525339 | ||
| Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients | Q37963138 | ||
| Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series | Q38505485 | ||
| Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district | Q38583014 | ||
| Osteonecrosis of the jaw a new complication related to Ipilimumab. | Q38865775 | ||
| Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series | Q39167132 | ||
| Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study | Q42829926 | ||
| Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series | Q42855416 | ||
| Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. | Q43266784 | ||
| Intravenous bisphosphonate-related osteonecrosis of the jaw: long-term follow-up of 109 patients | Q44838120 | ||
| Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection | Q45161882 | ||
| Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies | Q46167952 | ||
| Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid | Q46438797 | ||
| Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up | Q48418714 | ||
| Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. | Q50788126 | ||
| Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. | Q51522929 | ||
| Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays. | Q53095188 | ||
| Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics. | Q53198038 | ||
| Osteonecrosis of the jaw related to everolimus: a case report. | Q53313578 | ||
| Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases. | Q53816072 | ||
| The relationship of denosumab pharmacology and osteonecrosis of the jaws. | Q55056856 | ||
| American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update | Q56565081 | ||
| Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: Report of 2 cases with clinical implications | Q57904464 | ||
| Osteonecrosis of the Jaw Related to Bevacizumab | Q60386785 | ||
| Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases | Q62392239 | ||
| Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study | Q82032382 | ||
| Sunitinib related osteonecrosis of jaw: a case report | Q84323419 | ||
| Bisphosphonate-related osteonecrosis of the jaws--an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma | Q84564789 | ||
| Denosumab-related osteonecrosis of the jaw | Q84920561 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 440-445 | |
| P577 | publication date | 2018-02-14 | |
| P1433 | published in | Oral Surgery, Oral Medicine, Oral Pathology, and Oral Radiology | Q7099375 |
| P1476 | title | Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention | |
| P478 | volume | 125 |
| Q90179107 | Bone metastases in thyroid cancer | cites work | P2860 |
Search more.